The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 01, 2017

Filed:

Nov. 15, 2013
Applicant:

Samsung Electronics Co., Ltd., Suwon-si, Gyeonggi-do, KR;

Inventors:

Seung Hyun Lee, Suwon-si, KR;

Geun Woong Kim, Yongin-si, KR;

Kyung Ah Kim, Seongnam-si, KR;

Hye Won Park, Pyeongtaek-si, KR;

Ho Yeong Song, Seongnam-si, KR;

Young Mi Oh, Incheon, KR;

Saet Byoul Lee, Seoul, KR;

Ji Min Lee, Seoul, KR;

Kwang Ho Cheong, Seoul, KR;

Yun Ju Jeong, Hwaseong-si, KR;

Mi Young Cho, Seoul, KR;

Jae Hyun Choi, Seongnam-si, KR;

Yun Jeong Song, Seongnam-si, KR;

Yoon Aa Choi, Busan, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/437 (2006.01); A61K 31/517 (2006.01); A61K 31/44 (2006.01); C07K 16/28 (2006.01); C12N 5/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/517 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 16/2863 (2013.01); C12N 5/163 (2013.01); C07K 2317/24 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01);
Abstract

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.


Find Patent Forward Citations

Loading…